Участие различных популяций лимфоцитов в формировании защиты от менингококковой инфекции

Immunization of mice by synthetic peptides fragments of meningococcus external membrane fibers caused the expressed protection of animals against infection caused by live virulent meningococcus culture serogroup A, B and C. There are leading part T-lymphocytes in protection of mice from this infection here. The analysis of T-cellular populations by means of a method flowing cytophluorometrics has shown increase CD4+ and CD8+ lymphocytes without change of parity CD4+/CD8+. The increase in number of these lymphocytes occurred in late terms after immunization of mice.Целью настоящего исследования является изучение роли различных популяций лимфоцитов, принимающих участие в формировании иммунитета против менингококковой инфекции при иммунизации синтетическими пептидными фрагментами белков наружной мембраны менингококка серогруппы В. Иммунизация мышей синтетическими пептидными фрагментами белков наружной мембраны менингококка вызывала выраженную защиту животных от заражения живой вирулентной культурой менингококков серогрупп А, В и С. Показана ведущая роль Т-лимфоцитов в защите мышей от этой инфекции. Анализ Т-клеточных популяций с помощью метода проточной цитофлюорометрии показал изменение численности CD4+ и CD8+ лимфоцитов на разных этапах иммуногенеза без изменения соотношения CD4+/CD8+. Увеличение числа этих лимфоцитов происходило в поздние сроки после иммунизации мышей. Данные литературы указывают на роль PorA антигена в формировании Т-клеточного ответа. Тем не менее тип иммунного ответа на бактериальный менингит до сих пор до конца не ясен

Менингококковая поливакцина на основе очищенной IgAI протеазы

IgA1-protease allocated from the culture N. meningitidis serogroup A. As original materials were used three different intermediate products of vaccine production: cultural fluid, cetavlon supernatant and cetavlon precipitate. IgA1-protease was used to evaluate their protectivity and immunogenity. It was shown, that isolated IgA1 protease from the meningococcus serogroup A is able to protect mice, infected by meningococcus serogroup B.IgA1 протеаза, выделенная методами препаративной химии из промежуточных продуктов очистки менингококковой полисахаридной серогруппы А вакцины, обладает выраженной иммуногенной и протективной активностью для лабораторных мышей, обеспечивая их защиту от смертельного заражения вирулентными штаммами серогрупп А и В менингококков. Протективный эффект и нарастание анти-IgA1 антител позволяют прогнозировать вакцинные потенции изучаемого препарата, который может рассматриваться, в первую очередь, в качестве кандидата отсутствующей до настоящего времени менингококковой серогруппы В вакцины

Менингококковые вакцины: от капсульных полисахаридов до протеаз

Microbial capsular polysaccharides for many years provided a highly practical public health vaccines for preventing meningococcal, pneumococcal and Haemophilus influenza infection, and typhoid fever. Their application in the form of conjugates with protein carriers eliminate the gap in protection against these infections in children under one year. Extremely promising turned out offered us a new generation of vaccines, which have synthetic peptides conjugated to a meningococcal polysaccharide. Thus, new approaches to the solution of the problem of meningococcal disease vaccination serogroup B were open. In recent years, Russian researchers first suggested to use IgA1 protease (one of the major virulence factors of microbes and almost identical for mentioned below infections) for prevention of such diseases as meningococcal of all serogroups, pneumococcus and hemophilia infections. Patented processes for producing of the vaccine define domestic priority of its production and use.Микробные капсульные полисахариды на протяжении многих лет обеспечивали практическое здравоохранение высокоэффективными вакцинами для профилактики менингококковых, пневмококковых, гемофильных инфекций и брюшного тифа. А их применение в виде конъюгатов с белковыми носителями ликвидировало пробел при защите от этих инфекций детей в возрасте до одного года. Необычайно перспективным оказалось предложенное нами новое поколение вакцин, где уже синтетические пептиды конъюгировались с полисахаридами менингококков. Таким образом, были открыты подходы к решению проблемы вакцинопрофилактики менингококковой инфекции серогруппы В. В последние годы отечественные исследователи впервые предложили использовать для профилактики менингококковых инфекций всех серогрупп, а также инфекций, обусловленных пневмококками и гемофилами, один из главных факторов вирулентности этих микробов — IgA1 протеазу, практически идентичную для всей указанной группы инфекций. Запатентованные способы получения этой вакцины определяют отечественный приоритет ее производства и применения

Serological Analysis of Immunogenic Properties of Recombinant Meningococcus IgA1 Protease-Based Proteins

Using the genome sequence of IgA1 protease of N. meningitidis of serogroup B, four recombinant proteins of different structure and molecular weight were constructed. These proteins were equal in inducing the formation of specific antibodies to IgA1 protease and had protective properties against meningococci. In the sera of immunized mice, anti-IgA1 protease antibodies were detected by whole-cell ELISA, which indicated the presence of IgA1 protease on the surface of these bacteria. We hypothesized that the protective properties of IgA1 protease-based antigens and IgA1 protease analogs could be realized not only via impairment of bacterium adhesion to the mucosa, but also via suppression of this pathogen in the organism. The presented findings seem promising for using these proteins as the basis for anti-meningococcus vaccine. © 2016, Springer Science+Business Media New York

Induction of antimeningitis immunity by the synthetic peptides: I. The immunoactive synthetic fragments of porin A from Neisseria meningitidis

Fourteen peptides corresponding to sequences of all the exposed and some of the transmembrane protein regions of porin A from the outer membrane of Neisseria meningitidis strain B: 15:P1.7,16 were synthesized. Mice of various lines were immunized with the free peptides not conjugated with any protein carrier. It was shown that the majority of the peptides possess immunogenic properties. Two peptides were identified binding to antibodies present in the serum of mice after meningitis. Protective properties of a number of the synthesized peptides were studied, and three peptide sequences inducing mice protection to an experimental infection with N. meningitidis were identified. © 2000 MAIK "Nauka/Interperiodica"

Induction of antimeningitis immunity by the synthetic peptides. I. The immunoactive synthetic fragments of porin a from Neisseria meningitidis

Fourteen peptides corresponding to sequences of all the exposed and some of the transmembrane protein regions of porin A from the outer membrane of Neisseria meningitidis strain B:15:P1.7,16 were synthesized. Mice of various lines were immunized with the free peptides not conjugated with any protein carrier. It was shown that the majority of the peptides possess immunogenic properties. Two peptides were identified binding to antibodies present in the serum of mice after meningitis. Protective properties of a number of the synthesized peptides were studied, and three peptide sequences inducing mice protection from an experimental infection with N. meningitidis were identified

Serological Analysis of Immunogenic Properties of Recombinant Meningococcus IgA1 Protease-Based Proteins

Using the genome sequence of IgA1 protease of N. meningitidis of serogroup B, four recombinant proteins of different structure and molecular weight were constructed. These proteins were equal in inducing the formation of specific antibodies to IgA1 protease and had protective properties against meningococci. In the sera of immunized mice, anti-IgA1 protease antibodies were detected by whole-cell ELISA, which indicated the presence of IgA1 protease on the surface of these bacteria. We hypothesized that the protective properties of IgA1 protease-based antigens and IgA1 protease analogs could be realized not only via impairment of bacterium adhesion to the mucosa, but also via suppression of this pathogen in the organism. The presented findings seem promising for using these proteins as the basis for anti-meningococcus vaccine. © 2016, Springer Science+Business Media New York

Induction of antimeningitis immunity by the synthetic peptides. I. The immunoactive synthetic fragments of porin a from Neisseria meningitidis

Fourteen peptides corresponding to sequences of all the exposed and some of the transmembrane protein regions of porin A from the outer membrane of Neisseria meningitidis strain B:15:P1.7,16 were synthesized. Mice of various lines were immunized with the free peptides not conjugated with any protein carrier. It was shown that the majority of the peptides possess immunogenic properties. Two peptides were identified binding to antibodies present in the serum of mice after meningitis. Protective properties of a number of the synthesized peptides were studied, and three peptide sequences inducing mice protection from an experimental infection with N. meningitidis were identified